Patents by Inventor Douglas J. Demetrick

Douglas J. Demetrick has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7691632
    Abstract: The present invention relates to the discovery in eukaryotic cells, particularly mammalian cells, of a family of cell-cycle regulatory proteins (“CCR-proteins”). As described herein, this family of proteins includes a polypeptide having an apparent molecular weight of 16 kDa, and a polypeptide having an apparent molecular weight of approximately 15 kDa, each of which can function as an inhibitor of cell-cycle progression, and therefore ultimately of cell growth. The present invention comprises antibodies directed to such CCR-proteins. The present invention is directed to a kit for detecting the level of cyclin-dependent kinase inhibitor p16 gene expression comprising antibodies directed to a p16 protein.
    Type: Grant
    Filed: August 20, 2008
    Date of Patent: April 6, 2010
    Assignee: Cold Spring Harbor Laboratory
    Inventors: David H. Beach, Douglas J. Demetrick, Manuel Serrano, Gregory J. Hannon
  • Publication number: 20090170098
    Abstract: The present invention relates to the discovery in eukaryotic cells, particularly mammalian cells, of a family of cell-cycle regulatory proteins (“CCR-proteins”). As described herein, this family of proteins includes a polypeptide having an apparent molecular weight of 16 kDa, and a polypeptide having an apparent molecular weight of approximately 15 kDa, each of which can function as an inhibitor of cell-cycle progression, and therefore ultimately of cell growth. The present invention comprises antibodies directed to such CCR-proteins. The present invention is directed to a kit for detecting the level of cyclin-dependent kinase inhibitor p16 gene expression comprising antibodies directed to a p16 protein.
    Type: Application
    Filed: August 20, 2008
    Publication date: July 2, 2009
    Inventors: David H. Beach, Douglas J. Demetrick, Manuel Serrano, Gregory J. Hannon
  • Patent number: 7550561
    Abstract: The present invention relates to the discovery in eukaryotic cells, particularly human cells, a novel polypeptide of 16 kDa (hereinafter “p16INK4” or “p16”) can function as an inhibitor of cell cycle progression, and therefore ultimately of cell growth, and that similar to the role of p21 and p53, the p16 protein may function coordinately with the cell cycle regulatory protein, retinoblastoma (Rb).
    Type: Grant
    Filed: April 14, 1994
    Date of Patent: June 23, 2009
    Assignee: Cold Spring Harbor Laboratory
    Inventors: David H. Beach, Douglas J. Demetrick, Manuel Serrano, Gregory J. Hannon
  • Patent number: 7425617
    Abstract: The present invention relates to the discovery in eukaryotic cells, particularly mammalian cells, of a family of cell-cycle regulatory proteins (“CCR-proteins”). As described herein, this family of proteins includes a polypeptide having an apparent molecular weight of 16 kDa, and a polypeptide having an apparent molecular weight of approximately 15 kDa, each of which can function as an inhibitor of cell-cycle progression, and therefore ultimately of cell growth. The present invention comprises antibodies directed to such CCR-proteins.
    Type: Grant
    Filed: January 30, 1998
    Date of Patent: September 16, 2008
    Assignee: Cold Spring Harbor Laboratory
    Inventors: David H. Beach, Douglas J. Demetrick, Manuel Serrano, Gregory J. Hannon
  • Publication number: 20030100489
    Abstract: The present invention relates to the discovery in eukaryotic cells, particularly mammalian cells, of a novel family of cell-cycle regulatory proteins (“CCR-proteins”). As described herein, this family of proteins includes a polypeptide having an apparent molecular weight of 16 kDa, and a polypeptide having an apparent molecular weight of approximately 15 kDa, each of which can function as an inhibitor of cell-cycle progression, and therefore ultimately of cell growth. Thus, similar to the role of p21 to the p53 checkpoint, the subject CCR-proteins may function coordinately with the cell-cycle regulatory protein, retinoblastoma (RB). Furthermore, the CCR-protein family includes a protein having an apparent molecular weight of 13.5 kDa (hereinafter “p13.5”). The presumptive role of p13.5, like p16 and p15, is in the regulation of the cell-cycle.
    Type: Application
    Filed: September 4, 2001
    Publication date: May 29, 2003
    Inventors: David H. Beach, Douglas J. Demetrick, Manuel Serrano, Gregory J. Hannon
  • Patent number: 6486131
    Abstract: The present invention relates to the discovery in eukaryotic cells, particularly mammalian cells, of a novel family of cell-cycle regulatory proteins (“CCR-proteins”). As described herein, this family of proteins includes a polypeptide having an apparent molecular weight of 16 kDa, and a polypeptide having an apparent molecular weight of approximately 15 kDa, each of which can function as an inhibitor of cell-cycle progression, and therefore ultimately of cell growth. Thus, similar to the role of p21 to the p53 checkpoint, the subject CCR-proteins may function coordinately with the cell-cycle regulatory protein, retinoblastoma (RB). Furthermore, the CCR-protein family includes a protein having an apparent molecular weight of 13.5 kDa (hereinafter “p13.5”). The presumptive role of p13.5, like p16 and p15, is in the regulation of the cell-cycle.
    Type: Grant
    Filed: January 30, 1998
    Date of Patent: November 26, 2002
    Assignee: Cold Spring Harbor Laboratory
    Inventors: David H. Beach, Douglas J. Demetrick, Manuel Serrano, Gregory J. Hannon
  • Publication number: 20020082392
    Abstract: The present invention reldates to the discovery in eukaryotic cells, particularly mammalian cells, of a novel family of cell-cycle regulatory proteins (“CCR-proteins”). As described herein, this family of proteins includes a polypeptide having an apparent molecular weight of 16 kDa, and a polypeptide having an apparent molecular weight of approximately 15 kDa, each of which can function as an inhibitor of cell-cycle progression, and therefore ultimately of cell growth. Thus, similar to the role of p21 to the p53 checkpoint, the subject CCR-proteins may function coordinately with the cell-cycle regulatory protein, retinoblastoma (RB). Furthermore, the CCR-protein family includes a protein having an apparent molecular weight of 13.5 kDa (hereinafter “p13.5”). The presumptive role of p13.5, like p16 and p15, is in the regulation of the cell-cycle.
    Type: Application
    Filed: January 30, 1998
    Publication date: June 27, 2002
    Inventors: DAVID H. BEACH, DOUGLAS J. DEMETRICK, MANUEL SERRANO, GREGORY J. HANNON
  • Publication number: 20020025305
    Abstract: The present invention relates to the discovery in eukaryotic cells, particularly mammalian cells, of a novel family of cell-cycle regulatory proteins (“CCR-proteins”). As described herein, this family of proteins includes a polypeptide having an apparent molecular weight of 16 kDa, and a polypeptide having an apparent molecular weight of approximately 15 kDa, each of which can function as an inhibitor of cell-cycle progression, and therefore ultimately of cell growth. Thus, similar to the role of p21 to the p53 checkpoint, the subject CCR-proteins may function coordinately with the cell-cycle regulatory protein, retinoblastoma (RB). Furthermore, the CCR-protein family includes a protein having an apparent molecular weight of 13.5 kDa (hereinafter “p13.5”). The presumptive role of p13.5, like p16 and p15, is in the regulation of the cell-cycle.
    Type: Application
    Filed: January 30, 1998
    Publication date: February 28, 2002
    Inventors: DAVID H. BEACH, DOUGLAS J. DEMETRICK, MANUEL SERRANO, GREGORY J. HANNON
  • Patent number: 6331390
    Abstract: The present invention relates to the discovery in eukaryotic cells, particularly mammalian cells, of a novel family of cell-cycle regulatory proteins (“CCR-proteins”). As described herein, this family of proteins is characterized by four ankyrin repeats and the ability to bind to a cyclin dependent kinase (CDK). The family includes a polypeptide having an apparent molecular weight of 16 kDa, and a polypeptide having an apparent molecular weight of approximately 15 kDa, each of which can function as an inhibitor of cell-cycle progression, and therefore ultimately of cell growth. Thus, similar to the role of p21 to the p53 checkpoint, the subject CCR-proteins may function coordinately with the cell-cycle regulatory protein, retinoblastoma (RB).
    Type: Grant
    Filed: June 30, 1995
    Date of Patent: December 18, 2001
    Assignee: Cold Spring Harbor Laboratory
    Inventors: David H. Beach, Douglas J. Demetrick, Manuel Serrano, Gregory J. Hannon
  • Patent number: 6043030
    Abstract: The present invention relates to the discovery in eukaryotic cells, particularly mammalian cells, of a novel family of cell-cycle regulatory proteins ("CCR-proteins"). As described herein, this family of proteins is characterized by four ankyrin repeats and the ability to bind to a cyclin dependent kinase (CDK). The family includes a polypeptide having an apparent molecular weight of 16 kDa, and a polypeptide having an apparent molecular weight of approximately 15 kDa, each of which can function as an inhibitor of cell-cycle progression, and therefore ultimately of cell growth. Thus, similar to the role of p21 to the p53 checkpoint, the subject CCR-proteins may function coordinately with the cell-cycle regulatory protein, retinoblastoma (RB).
    Type: Grant
    Filed: January 2, 1996
    Date of Patent: March 28, 2000
    Assignee: Cold Spring Harbor Laboratory
    Inventors: David H. Beach, Douglas J. Demetrick, Manuel Serrano, Gregory J. Hannon
  • Patent number: 5968821
    Abstract: The present invention relates to the discovery in eukaryotic cells, particularly mammalian cells, of a novel family of cell-cycle regulatory proteins ("CCR-proteins"). As described herein, this family of proteins includes a polypeptide having an apparent molecular weight of 16 kDa, and a polypeptide having an apparent molecular weight of approximately 15 kDa, each of which can function as an inhibitor of cell-cycle progression, and therefore ultimately of cell growth. Thus, similar to the role of p21 to the p53 checkpoint, the subject CCR-proteins may function coordinately with the cell-cycle regulatory protein, retinoblastoma (RB). Furthermore, the CCR-protein family includes a protein having an apparent molecular weight of 13.5 kDa (hereinafter "p13.5"). The presumptive role of p13.5, like p16 and p15, is in the regulation of the cell-cycle.
    Type: Grant
    Filed: July 15, 1997
    Date of Patent: October 19, 1999
    Assignee: Cold Spring Harbor Laboratories, Inc.
    Inventors: David H. Beach, Douglas J. Demetrick, Manuel Serrano, Gregory J. Hannon
  • Patent number: 5962316
    Abstract: The present invention relates to the discovery in eukaryotic cells, particularly mammalian cells, of a novel family of cell-cycle regulatory proteins ("CCR-proteins"). As described herein, this family of proteins includes a polypeptide having an apparent molecular weight of 16 kDa, and a polypeptide having an apparent molecular weight of approximately 15 kDa, each of which can function as an inhibitor of cell-cycle progression, and therefore ultimately of cell growth. Thus, similar to the role of p21 to the p53 checkpoint, the subject CCR-proteins may function coordinately with the cell-cycle regulatory protein, retinoblastoma (RB). Furthermore, the CCR-protein family includes a protein having an apparent molecular weight of 13.5 kDa (hereinafter "p13.5"). The presumptive role of p13.5, like p16 and p15, is in the regulation of the cell-cycle.
    Type: Grant
    Filed: September 14, 1994
    Date of Patent: October 5, 1999
    Assignee: Cold Spring Harbor Laboratory
    Inventors: David H. Beach, Douglas J. Demetrick, Manuel Serrano, Gregory J. Hannon
  • Patent number: 5889169
    Abstract: The present invention relates to the discovery in eukaryotic cells, particularly mammalian cells, of a novel family of cell-cycle regulatory proteins ("CCR-proteins"). As described herein, these family of proteins includes a polypeptide having an apparent molecular weight of 16 kDa (hereinafter "p16.sup.INK4 " OR "p16") and which can function as an inhibitor of cell-cycle progression, and therefore ultimately of cell growth, and that similar to role of p21 and p53, the p16 protein may function coordinately with the cell cycle regulatory protein, retinoblastoma (Rb). Furthermore, the CCR-protein family includes a protein having an apparent molecular weight of 13.5 kDa (hereinafter "p13.5"). The presumptive role of p13.5, like p16, is in the regulation of the cell-cycle.
    Type: Grant
    Filed: May 25, 1994
    Date of Patent: March 30, 1999
    Assignee: Cold Spring Harbor Laboratory
    Inventors: David H. Beach, Douglas J. Demetrick, Manuel Serrano, Gregory J. Hannon, Dawn E. Quelle, Charles J. Sherr